ESMO26: Toni Choueiri, MD, on KEYNOTE-564 - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ESMO26: Toni Choueiri, MD, on KEYNOTE-564

  • November 17, 2026

Share

  • 1

    Toni Choueiri, MD, presented the final analysis of the KEYNOTE-564 trial in kidney cancer.

  • 2

    The analysis followed patients for 7 years.

  • 3

    The trial evaluated adjuvant pembrolizumab in high-risk clear-cell renal cell carcinoma.

  • 4

    Adjuvant pembrolizumab continued to extend disease-free survival.

  • 5

    Adjuvant pembrolizumab continued to extend overall survival.

Original Source(s)

Related Content